Current situations and the future prospect of monoclonal antibody products

Bulletin of National Institute of Health Sciences

Volumn , Issue 132, 2014, Pages 36-46

  Yamaguchi, Teruhide ^a  

^a NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

Author keywords

Antibody drug conjugate; Biosimilar; Monoclonal antibody

Indexed keywords

EID: 84921925658     PISSN: 13434292     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Shinkawa, T.; Nakamura, K.; Yamane, N.; Shoji-Hosaka, E.; Kanda, Y.; Sakurada, M.; Uchida, K.; Anazawa, H.; Satoh, M.; Yamasaki, M. The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem., 278, 3466-3473. (2003)
2. Niwa, R.; Sakurada, M.; Kobayashi, Y.; Uehara, A.; Matsushima, K.; Ueda, R.; Nakamura, K.; Shitara, K. Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density. Clin. Cancer Res., 11, 2327-2336 (2005)
3. Naoko Yamane-Ohnuki and Mitsuo Satoh; Production of therapeutic antibodies with controlled fucosylation. mAbs., 2009, 1(3): 230-236
4. Igawa et. Al., Nature Biotechnology, 28, 1203-1207 (2010)
5. Kitazawa et al; A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nature Medicine 18, 1570-1574 (2012)
6. Schuurman, J., Graus, Y.F., Labrijn, A.F., Ruuls, S.R., Parren, P.W.: Opening the door to innovation. mAbs., 6, 812-819 (2014)
7. Furusho, K., Nakano, H., Shinomiya, K., Tamura, T.: High-dose intravenous gammaglobulin for Kawasaki disease. The Lancet 324, 1055-1058 (1984)
8. Mullard, A.: Maturing antibody-drug conjugate pipeline hits 30. Drug Discovery (Nature review), 12, 329-333 (2013)
9. Lipson, E.J., Drake, C.G.: Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin.Cancer Res., 17, 6958-6962 (2011)
10. Rosenberg, S.A., Restifo, N.P., Yang, J.C., Morgan, R.A., Mark E., Dudley, M.E.: Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nature Reviews Cancer 8, 299-308 (2008)
11. Seremet, T, Brasseur, F, Coulie, PG.: Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy. Cancer J., 17(5):325-330 (2011)
12. Coulie, P.G., Van den Eynde, B.J., van der Bruggen, P., Boon, T.: Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nature Reviews Cancer 14, 135-146 (2014)
13. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003073.pdf
14. http://www.pmda.go.jp/kijunsakusei/file/guideline/quality/koutai-hyouka_guidance.pdf
15. Morrow, K.J. Jr., Rathin C., Das, R.C.: Therapeutic Antibodies in Review. Innovative products and a range of indications drive the therapeutic antibody market. BioPharm International 26, 34-40 (2013)
16. Lipson EJ, Drake CG.; Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma. Clin Cancer Res. 17, 6958-6962. 2011
17. Yi-chi M. Kong and Jeffrey C. Flynn: Opportunistic autoimmune disorders potentiated by immunecheckpoint inhibitors anti-CTLA-4 and anti-PD-1. Front. Immunol., 10.3389/fimmu.2014.00206 (2014)
18. Ignacio Melero, Antonio M. Grimaldi, Jose L. Perez-Gracia, Paolo A. Ascierto: Clinical Development of Immunostimulatory Monoclonal Antibodies and Opportunities for Combination. Clin Cancer Res. 19, 997-1008. 2013
19. Weber, J.S., Kähler, K.C., Hauschild, A.: Management of immune-related adverse events and kinetics of response with Ipilimumab. Am. Soc. Clin. Oncol., 30, 2691-2697 (2012)
20. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002576/WC500151486.pdf
21. Eisenhauera, E.A. et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228-247 (2009)